Aveo's Tivozanib Under CHMP Spotlight If Negative OS Trend Continues In TIVO-3

 
• By John Davis

An August 2019 analysis of overall survival in the TIVO-3 study of Aveo’s tivozanib in advanced renal cell carcinoma is now an interim rather than a final analysis, but EU regulators may take action if a negative overall survival trend is found to be continuing.  

GreenPawn
Improved survival is a key measure for regulators and patients alike. • Source: Shutterstock

More from Anticancer

More from Therapy Areas